

ASX ANNOUNCEMENT

VIRTUS HEALTH LIMITED (ASX:VRT)

30 August 2021

VIRTUS HEALTH BOARD RENEWAL WITH APPOINTMENT OF TWO NEW INDEPENDENT NON EXECUTIVE DIRECTORS

- Virtus Health appoints Ms Cathy Aston and Dr Priscilla Rogers as independent non-executive directors
- Virtus Health Board now has seven experienced directors; including four independent non-executive directors and an independent Chair.

Global assisted reproductive services company Virtus Health (“Virtus”) (ASX:VRT) is pleased to announce the appointment of two independent non-executive directors to its Board.

Virtus Health Chair, Sonia Petering, welcomed the appointments: “We are delighted to welcome Cathy and Priscilla to the Virtus Health Board as non-executive directors. They both come from diverse career backgrounds and experience and will each bring valuable perspective, skill and expertise to Virtus Health.

“Pleasingly, with these appointments, two-thirds of the Virtus Health Board of Directors are now women, reflecting the Virtus Health’s workforce and customer base. We are proud to be an organisation with such strong representation of women in leadership,” Ms Petering said.

Both Ms Aston and Dr Rogers will join the Virtus Board with effect from 1 September 2021.

Ms Cathy Aston

Cathy comes to the Virtus Board having had an extensive executive career at Telstra where she moved across roles in finance, marketing and strategy, including as the Finance Director of the International Division where she was based in Hong Kong and New Delhi and as Chief Executive of a mobile phone company based in Colombo. Cathy’s executive roles each had a focus on enabling the business to improve its customer service and to operate more effectively and efficiently through better use of technology.

Since 2013, Cathy has held a range of non-executive director roles and has also worked as a business advisor with a range of clients. Most recently, Cathy has worked with the NSW Government to improve outcomes across an array of programs and is currently a non-executive director with Macquarie Investment Management Ltd, IMB Bank Ltd, IVE Group (ASX: IGL) and Over the Wire Holdings (ASX: OTW), with the latter two roles also including Chair of Audit, Risk and Compliance committees. Cathy’s non-executive director experience includes serving as an Advisory Board Member of Avanseus, an AI business based out of Singapore.

Dr Priscilla Rogers

As an engineer and an entrepreneur, Priscilla has had direct experience in how technology innovation can transform industries and improve lives. With a PhD in engineering, she has spent her career in the research, development and translation of new technologies including medical devices, artificial intelligence (AI) and digital health solutions, including leading the Cognitive Health & Life Sciences portfolio at IBM Research Australia.

Priscilla is currently a director and co-founder of Doftek, which is commercialising the world's first active wheel alignment systems for vehicles; as well as a director and co-founder of Grean Brands, which is a health and wellness company responsible for developing and commercialising new antimicrobial prevention products. Priscilla previously co-founded IntelliMedical, which successfully developed steerable guidewires for minimally invasive surgical procedures and was acquired by Merit Medical (NASDAQ: MMSI) in 2017. Priscilla's non-executive director roles include serving on the Board of the Digital Health Cooperative Research Centre and the Board of Australian Dementia Network Limited.

In accordance with the constitution of Virtus Health and Listing Rule 14.4, members of Virtus Health will be invited to vote on both the election of Ms Aston and Dr Rogers as directors at the Annual General Meeting of Virtus Health Limited to be held on 18 November 2021.

This announcement is authorised by the Board of Directors of Virtus Health.

-ENDS-

For further information, please contact:

Angela Read PR and Media Specialist, Virtus Health +61 (0)428 448 719
angela.read@virtushealth.com.au

About Virtus Health Limited (ASX:VRT) brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related specialised diagnostic and day hospital services. We have developed one of the most successful ARS collaborations in the world. With 128 of the world's leading fertility specialists supported by over 1300 professional staff, we are the largest network and provider of fertility services in Australia, Ireland and Denmark, Singapore and UK.